Type II transglutaminase stimulates epidermal cancer stem cell epithelial-mesenchymal transition

Oncotarget

Volumn 6, Issue 24, 2015, Pages 20525-20539

  Fisher, Matthew L ^a   Adhikary, Gautam ^a   Xu, Wen ^a   Kerr, Candace ^a   Keillor, Jeffrey W ^c   Eckert, Richard L ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

^c UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Cancer stem cell; Epidermal squamous cell carcinoma; Epithelial mesenchymal transition; TG2; Type II transglutaminase

Indexed keywords

ENZYME INHIBITOR; FIBRONECTIN; GUANOSINE TRIPHOSPHATE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NERVE CELL ADHESION MOLECULE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR TWIST; TRANSGLUTAMINASE 2 INHIBITOR; UNCLASSIFIED DRUG; VIMENTIN; GUANINE NUCLEOTIDE BINDING PROTEIN; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE;

A431 CELL LINE; ARTICLE; BREAST CANCER; CANCER CELL LINE; CANCER STEM CELL; CELL INVASION; CELL MIGRATION; CELL STIMULATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME BINDING; EPIDERMAL CANCER; EPITHELIAL MESENCHYMAL TRANSITION; GENE SILENCING; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SKIN CANCER; SKIN CARCINOMA; ENZYMOLOGY; EPITHELIUM CELL; HEK293 CELL LINE; METABOLISM; PATHOLOGY; SQUAMOUS CELL CARCINOMA;

CARCINOMA, SQUAMOUS CELL; EPITHELIAL CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; GTP-BINDING PROTEINS; HEK293 CELLS; HUMANS; NEOPLASTIC STEM CELLS; SIGNAL TRANSDUCTION; TRANSGLUTAMINASES;

EID: 84940172102     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3890     Document Type: Article

References (52)

1. Christenson LJ, Borrowman TA, Vachon CM, Tollefson MM, Otley CC, Weaver AL, Roenigk RK. Incidence of basal cell and squamous cell carcinomas in a population younger than 40 years. JAMA. 2005; 294:681-690.
2. Moller R, Reymann F, Hou-Jensen K. Metastases in dermatological patients with squamous cell carcinoma. Arch Dermatol. 1979; 115:703-705.
3. Adhikary G, Grun D, Kerr C, Balasubramanian S, Rorke EA, Vemuri M, Boucher S, Bickenbach JR, Hornyak T, Xu W, Fisher ML, Eckert RL. Identification of a population of epidermal squamous cell carcinoma cells with enhanced potential for tumor formation. PLoS One. 2013; 8:e84324.
4. Samatov TR, Tonevitsky AG, Schumacher U. Epithelial-mesenchymal transition: focus on metastatic cascade, alternative splicing, non-coding RNAs and modulating compounds. Mol Cancer. 2013; 12:107.
5. Chaffer CL, Thompson EW, Williams ED. Mesenchymal to epithelial transition in development and disease. Cells Tissues Organs. 2007; 185:7-19.
6. Zeisberg EM, Tarnavski O, Zeisberg M, Dorfman AL, McMullen JR, Gustafsson E, Chandraker A, Yuan X, Pu WT, Roberts AB, Neilson EG, Sayegh MH, Izumo S, et al. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med. 2007; 13:952-961.
7. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002; 2:442-454.
8. Lee JM, Dedhar S, Kalluri R, Thompson EW. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol. 2006; 172:973-981.
9. Kumar A, Xu J, Brady S, Gao H, Yu D, Reuben J, Mehta K. Tissue transglutaminase promotes drug resistance and invasion by inducing mesenchymal transition in mammary epithelial cells. PLoS One. 2010; 5:e13390.
10. Kumar A, Xu J, Sung B, Kumar S, Yu D, Aggarwal BB, Mehta K. Evidence that GTP-binding domain but not catalytic domain of transglutaminase 2 is essential for epithelial-to-mesenchymal transition in mammary epithelial cells. Breast Cancer Res. 2012; 14:R4.
11. Lin CY, Tsai PH, Kandaswami CC, Chang GD, Cheng CH, Huang CJ, Lee PP, Hwang JJ, Lee MT. Role of tissue transglutaminase 2 in the acquisition of a mesenchymal-like phenotype in highly invasive A431 tumor cells. Mol Cancer. 2011; 10:87.
12. Shao M, Cao L, Shen C, Satpathy M, Chelladurai B, Bigsby RM, Nakshatri H, Matei D. Epithelial-to-mesenchymal transition and ovarian tumor progression induced by tissue transglutaminase. Cancer Res. 2009; 69:9192-9201.
13. Sarkar NK, Clarke DD, Waelsch H. An enzymically catalyzed incorporation of amines into proteins. Biochim Biophys Acta. 1957; 25:451-452.
14. Nakaoka H, Perez DM, Baek KJ, Das T, Husain A, Misono K, Im MJ, Graham RM. Gh: a GTP-binding protein with transglutaminase activity and receptor signaling function. Science. 1994; 264:1593-1596.
15. Pierce A, Whetton AD, Meyer S, Ravandi-Kashani F, Borthakur G, Coombes KR, Zhang N, Kornblau S. Transglutaminase 2 expression in acute myeloid leukemia: association with adhesion molecule expression and leukemic blast motility. Proteomics. 2013; 13:2216-2224.
16. Mangala LS, Fok JY, Zorrilla-Calancha IR, Verma A, Mehta K. Tissue transglutaminase expression promotes cell attachment, invasion and survival in breast cancer cells. Oncogene. 2007; 26:2459-2470.
17. Kumar A, Gao H, Xu J, Reuben J, Yu D, Mehta K. Evidence that aberrant expression of tissue transglutaminase promotes stem cell characteristics in mammary epithelial cells. PLoS One. 2011; 6:e20701.
18. Kumar S, Mehta K. Tissue transglutaminase, inflammation, and cancer: how intimate is the relationship? Amino Acids. 2013; 44:81-88.
19. Cao L, Shao M, Schilder J, Guise T, Mohammad KS, Matei D. Tissue transglutaminase links TGF-beta, epithelial to mesenchymal transition and a stem cell phenotype in ovarian cancer. Oncogene. 2012; 31:2521-2534.
20. Park MK, You HJ, Lee HJ, Kang JH, Oh SH, Kim SY, Lee CH. Transglutaminase-2 induces N-cadherin expression in TGF-beta1-induced epithelial mesenchymal transition via c-Jun-N-terminal kinase activation by protein phosphatase 2A down-regulation. Eur J Cancer. 2013; 49:1692-1705.
21. Eckert RL, Kaartinen MT, Nurminskaya M, Belkin AM, Colak G, Johnson GV, Mehta K. Transglutaminase regulation of cell function. Physiol Rev. 2014; 94:383-417.
22. Fesus L, Piacentini M. Transglutaminase 2: an enigmatic enzyme with diverse functions. Trends Biochem Sci. 2002; 27:534-539.
23. Ientile R, Caccamo D, Griffin M. Tissue transglutaminase and the stress response. Amino Acids. 2007; 33:385-394.
24. Kalluri R. EMT: when epithelial cells decide to become mesenchymal-like cells. J Clin Invest. 2009; 119:1417-1419.
25. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009; 119:1420-1428.
26. Tam WL, Weinberg RA. The epigenetics of epithelial-mesenchymal plasticity in cancer. Nat Med. 2013; 19:1438-1449.
27. Keillor J, Chica R, Chabot N, Vinci V, Pardin C, Fortin E, Gillet S, Nakano Y, Kaartinen M, Pelletier J, Lubell W. The bioorganic chemistry of transglutaminase-from mechanism to inhibition and engineering. Can J Chem. 2008; 86:271-276.
28. Caron NS, Munsie LN, Keillor JW, Truant R. Using FLIM-FRET to measure conformational changes of transglutaminase type 2 in live cells. PLoS One. 2012; 7:e44159.
29. Gundemir S, Colak G, Tucholski J, Johnson GV. Transglutaminase 2: a molecular Swiss army knife. Biochim Biophys Acta. 2012; 1823:406-419.
30. Gundemir S, Johnson GV. Intracellular localization and conformational state of transglutaminase 2: implications for cell death. PLoS One. 2009; 4:e6123.
31. Gundemir S, Colak G, Feola J, Blouin R, Johnson GV. Transglutaminase 2 facilitates or ameliorates HIF signaling and ischemic cell death depending on its conformation and localization. Biochim Biophys Acta. 2013; 1833:1-10.
32. Agnihotri N, Kumar S, Mehta K. Tissue transglutaminase as a central mediator in inflammation-induced progression of breast cancer. Breast Cancer Res. 2013; 15:202.
33. Kumar S, Mehta K. Tissue Transglutaminase Constitutively Activates HIF-1alpha Promoter and Nuclear Factor-kappaB via a Non-Canonical Pathway. PLoS One. 2012; 7:e49321.
34. Kim DS, Han BG, Park KS, Lee BI, Kim SY, Bae CD. I-kappaBalpha depletion by transglutaminase 2 and mu-calpain occurs in parallel with the ubiquitin-proteasome pathway. Biochem Biophys Res Commun. 2010; 399:300-306.
35. Kim JM, Voll RE, Ko C, Kim DS, Park KS, Kim SY. A new regulatory mechanism of NF-kappaB activation by I-kappaBbeta in cancer cells. J Mol Biol. 2008; 384:756-765.
36. Brown KD. Transglutaminase 2 and NF-kappaB: an odd couple that shapes breast cancer phenotype. Breast Cancer Res Treat. 2013; 137:329-336.
37. Cao L, Petrusca DN, Satpathy M, Nakshatri H, Petrache I, Matei D. Tissue transglutaminase protects epithelial ovarian cancer cells from cisplatin-induced apoptosis by promoting cell survival signaling. Carcinogenesis. 2008; 29:1893-1900.
38. Yakubov B, Chelladurai B, Schmitt J, Emerson R, Turchi JJ, Matei D. Extracellular tissue transglutaminase activates noncanonical NF-kappaB signaling and promotes metastasis in ovarian cancer. Neoplasia. 2013; 15:609-619.
39. Micalizzi DS, Farabaugh SM, Ford HL. Epithelial-mesenchymal transition in cancer: parallels between normal development and tumor progression. J Mammary Gland Biol Neoplasia. 2010; 15:117-134.
40. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009; 139:871-890.
41. Voulgari A, Pintzas A. Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochim Biophys Acta. 2009; 1796:75-90.
42. Wang Y, Shi J, Chai K, Ying X, Zhou BP. The Role of Snail in EMT and Tumorigenesis. Curr Cancer Drug Targets. 2013; 13:963-972.
43. Al-Jallad HF, Myneni VD, Piercy-Kotb SA, Chabot N, Mulani A, Keillor JW, Kaartinen MT. Plasma membrane factor XIIIA transglutaminase activity regulates osteoblast matrix secretion and deposition by affecting microtubule dynamics. PLoS One. 2011; 6:e15893.
44. Colak G, Keillor JW, Johnson GV. Cytosolic guanine nucledotide binding deficient form of transglutaminase 2 (R580a) potentiates cell death in oxygen glucose deprivation. PLoS One. 2011; 6:e16665.
45. Clouthier CM, Mironov GG, Okhonin V, Berezovski MV, Keillor JW. Real-time monitoring of protein conformational dynamics in solution using kinetic capillary electrophoresis. Angew Chem Int Ed Engl. 2012; 51:12464-12468.
46. van RF, Berx G. The cell-cell adhesion molecule E-cadherin. Cell Mol Life Sci. 2008; 65:3756-3788.
47. Milakovic T, Tucholski J, McCoy E, Johnson GV. Intracellular localization and activity state of tissue transglutaminase differentially impacts cell death. J Biol Chem. 2004; 279:8715-8722.
48. Satpathy M, Cao L, Pincheira R, Emerson R, Bigsby R, Nakshatri H, Matei D. Enhanced peritoneal ovarian tumor dissemination by tissue transglutaminase. Cancer Res. 2007; 67:7194-7202.
49. Poligone B, Hayden MS, Chen L, Pentland AP, Jimi E, Ghosh S. A role for NF-kappaB activity in skin hyperplasia and the development of keratoacanthomata in mice. PLoS One. 2013; 8:e71887.
50. Dajee M, Lazarov M, Zhang JY, Cai T, Green CL, Russell AJ, Marinkovich MP, Tao S, Lin Q, Kubo Y, Khavari PA. NF-kappaB blockade and oncogenic Ras trigger invasive human epidermal neoplasia. Nature. 2003; 421:639-643.
51. Adhikary G, Chew YC, Reece EA, Eckert RL. PKC-delta and-eta, MEKK-1, MEK-6, MEK-3, and p38-delta Are Essential Mediators of the Response of Normal Human Epidermal Keratinocytes to Differentiating Agents. J Invest Dermatol. 2010.
52. Han B, Rorke EA, Adhikary G, Chew YC, Xu W, Eckert RL. Suppression of AP1 transcription factor function in keratinocyte suppresses differentiation. PLoS One. 2012; 7:e36941.